|Articles|February 9, 2022
- Pharmaceutical Executive-02-01-2022
- Volume 42
- Issue 2
Pharmaceutical Executive, February 2022 Issue (PDF)
Click the title above for a link to open the Pharmaceutical Executive February 2022 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 4 years ago
As Change Continues, Are You Digitally Fit For the Future?almost 4 years ago
Ready for Pharma’s Next Chapteralmost 4 years ago
The Tech Perspective: Coordinating a Plan of Engagementalmost 4 years ago
The Importance of Culturally Inclusive and Relevant Marketingalmost 4 years ago
Messaging Makeoveralmost 4 years ago
Ethics of Antibioticsalmost 4 years ago
What’s Up in Biotech These Days? Not Much, Unfortunatelyalmost 4 years ago
Planning for Second to Market in Orphan Disease Spacealmost 4 years ago
AI and Analytics Appear Ready to Surge in Sales and Marketingalmost 4 years ago
It’s Time for Companies To See Employees as Full-Time PeopleNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
FDA Appoints Tracy Beth Høeg as Acting Director of CDER
2
Mark Cuban Pushes for Generic Drug Fee Waivers, as Cost Plus Drugs Eyes US Manufacturing Expansion
3
Five Steps for Successful CGT Commercialization Through Health Systems Partnerships
4
FDA Approves Expanded Indication of Jaypirca for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
5
